Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2016 - 2026)

Amphastar Pharmaceuticals has reported Free Cash Flow over the past 13 years, most recently at $31.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 90.51% year-over-year to $31.6 million; the TTM value through Dec 2025 reached $148.4 million, down 13.91%, while the annual FY2025 figure was $148.4 million, 13.91% down from the prior year.
  • Free Cash Flow for Q4 2025 was $31.6 million at Amphastar Pharmaceuticals, down from $52.1 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $63.5 million in Q3 2023 and troughed at -$9.8 million in Q4 2023.
  • A 5-year average of $31.0 million and a median of $33.6 million in 2023 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: crashed 246.41% in 2021 and later skyrocketed 2274.78% in 2023.
  • Year by year, Free Cash Flow stood at $51.5 million in 2021, then tumbled by 110.43% to -$5.4 million in 2022, then crashed by 82.37% to -$9.8 million in 2023, then skyrocketed by 269.42% to $16.6 million in 2024, then surged by 90.51% to $31.6 million in 2025.
  • Business Quant data shows Free Cash Flow for AMPH at $31.6 million in Q4 2025, $52.1 million in Q3 2025, and $40.2 million in Q2 2025.